Steven Talbert is an assistant clinical professor, Christine Wargo Detrick is a doctoral student, and Kimberly Emery is a doctoral candidate, University of Central Florida College of Nursing, Orlando, Florida.
Aurea Middleton is a clinical research coordinator, Orlando Regional Medical Center, Orlando, Florida.
Am J Crit Care. 2020 Sep 1;29(5):371-378. doi: 10.4037/ajcc2020129.
Patients experience endotracheal intubation in various settings with wide-ranging risks for postintubation complications such as aspiration and ventilator-associated conditions.
To evaluate associations between intubation setting, presence of aspiration biomarkers, and clinical outcomes.
This study is a subanalysis of data from the NO-ASPIRATE single-blinded randomized clinical trial. Data were prospectively collected for 513 adult patients intubated within 24 hours of enrollment. Patients with documented aspiration events at intubation were excluded. In the NO-ASPIRATE trial, intervention patients received enhanced oropharyngeal suctioning every 4 hours and control patients received sham suctioning. Tracheal specimens for α-amylase and pepsin tests were collected upon enrollment. Primary outcomes were ventilator hours, lengths of stay, and rates of ventilator-associated conditions.
Of the baseline tracheal specimens, 76.4% were positive for α-amylase and 33.1% were positive for pepsin. Proportions of positive tracheal α-amylase and pepsin tests did not differ significantly between intubation locations (study hospital, transfer from other hospital, or field intubation). No differences were found for ventilator hours or lengths of stay. Patients intubated at another hospital and transferred had significantly higher ventilator-associated condition rates than did those intubated at the study hospital (P = .02). Ventilator-associated condition rates did not differ significantly between patients intubated in the field and patients in other groups.
Higher ventilator-associated condition rates associated with interhospital transfer may be related to movement from bed, vehicle loading and unloading, and transport vehicle vibrations. Airway assessment and care may also be suboptimal in the transport environment.
患者在各种环境下经历气管插管,存在广泛的并发症风险,如吸入和呼吸机相关条件。
评估插管环境、存在吸入生物标志物与临床结果之间的关系。
这是一项对 NO-ASPIRATE 单盲随机临床试验数据的亚分析。前瞻性收集了 513 名在入组后 24 小时内插管的成年患者的数据。将有记录的插管时吸入事件的患者排除在外。在 NO-ASPIRATE 试验中,干预组患者每 4 小时接受增强型口咽抽吸,对照组患者接受模拟抽吸。在入组时采集气管标本进行α-淀粉酶和胃蛋白酶检测。主要结局为通气时间、住院时间和呼吸机相关条件的发生率。
在基线时的气管标本中,76.4%的标本α-淀粉酶检测呈阳性,33.1%的标本胃蛋白酶检测呈阳性。气管α-淀粉酶和胃蛋白酶检测阳性的比例在插管部位(研究医院、从其他医院转来或现场插管)之间无显著差异。通气时间或住院时间无显著差异。在其他医院插管并转来的患者与在研究医院插管的患者相比,呼吸机相关条件的发生率显著更高(P=0.02)。在现场插管的患者与其他组的患者相比,呼吸机相关条件的发生率无显著差异。
与医院间转院相关的呼吸机相关条件发生率较高可能与从病床转移、车辆装卸和运输车辆振动有关。在转运环境中,气道评估和护理也可能不够完善。